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DObjectives: We sought to compare long-term outcomes after coronary bypass surgery with and without an
internal thoracic artery graft.
Methods: We analyzed clinical outcomes over a median follow-up of 6.7 years among 3,087 patients who re-
ceived coronary bypass surgery as participants in one of 8 clinical trials comparing surgical intervention with
angioplasty. We used 2 statistical methods (covariate adjustment and propensity score matching) to adjust for
the nonrandomized selection of internal thoracic artery grafts.
Results: Internal thoracic artery grafting was associated with lower mortality, with hazard ratios of 0.77 (con-
fidence interval, 0.62–0.97; P¼ .02) for covariate adjustment and 0.77 (confidence interval, 0.57–1.05; P¼ .10)
for propensity score matching. The composite end point of death or myocardial infarction was reduced to a sim-
ilar extent, with hazard ratios of 0.83 (confidence interval, 0.69–1.00; P ¼ .05) for covariate adjustment to 0.78
(confidence interval, 0.61–1.00; P¼ .05) for propensity score matching. There was a trend toward less angina at
1 year, with odds ratios of 0.81 (confidence interval, 0.61–1.09; P ¼ .16) in the covariate-adjusted model and
0.81 (confidence interval, 0.55–1.19; P ¼ .28) in the propensity score–adjusted model.
Conclusions: Use of an internal thoracic artery graft during coronary bypass surgery seems to improve long-
term clinical outcomes. (J Thorac Cardiovasc Surg 2011;142:829-35)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and Caonary artery bypass graft surgery (CABG).1-3 Although it is
widely believed that this higher patency rate leads to better
long-term clinical outcomes, there are few data to support
this assumption. Only one small randomized trial has com-
pared use of ITA grafts with use of saphenous vein grafts.4
In that trial patients assigned to receive an ITA graft had
fewer composite end points of cardiac death, myocardial in-
farction, repeat revascularization, and cardiac hospitalization
over 10 years (12/39 vs 21/41, P< .05) but did not differ
significantly in any other end point. The results of this trial
are not definitive because of its small size and because the
outcome differences were driven mostly by cardiac hospital-
izations rather than death or myocardial infarction. Observa-
tional nonrandomized studies of between 743 and 5,931
patients who underwent CABG in the 1970s suggest that
patients who received an ITA graft had improved long-
term survival compared with that of patients who received
only saphenous vein grafts.5-7 Patients selected to receive
an ITA graft, however, differed in many clinical
characteristics from patients selected to receive only vein
grafts, and these differences might have introduced
selection bias into the comparison of outcomes that can be
difficult to control by using statistical methods. Newer
approaches to the analysis of observational data might help
control for differences between patients selected for
different treatments,8-11 although selection biases notrdiovascular Surgery c Volume 142, Number 4 829
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CABG ¼ coronary artery bypass graft surgery
MI ¼ myocardial infarction
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Dcaptured by measured covariates might still exist.12 The
purpose of this study was to apply both propensity score
methods and covariate adjustment methods to compare the
long-term outcomes of a more contemporary sample of
patients who underwent CABGwith or without an ITA graft.
MATERIALS AND METHODS
Investigators from 10 randomized trials of CABG versus percutaneous
coronary intervention for multivessel coronary disease pooled individual
patient data as part of a collaborative analysis of long-term treatment out-
comes, as described previously.13 The present study is based on data from
the 8 trials that provided individual patient data on the use of ITA grafts
among patients assigned to CABG.13 Use of ITA grafting in these trials
was based on the surgeon’s preference and was not randomized.
We used multivariable logistic regression to compare baseline clinical
characteristics of patients who received an ITA graft with those who did
not. The results of this model were used to create a propensity score that
estimated the probability of each patient receiving an ITA graft. For the
propensity score–matched analyses, we identified pairs of patients, one
of whom received an ITA graft and one of whom did not, using an algo-
rithm14 that first paired the patients with the closest propensity scores,
then paired the patients with the next closest propensity scores, and soTABLE 1. Baseline characteristics by use of ITA
All patients
No ITA (n ¼ 514) ITA (n ¼ 2,573)
Age, y (mean) 61.0 60.3
Female sex 30% 22%
Diabetes 17% 16%
Hypertension 45% 46%
Hyperlipidemia 52% 53%
Current smoker 22% 25%
Proximal LAD 35% 52%
3-Vessel disease 29% 39%
Unstable angina 49% 46%
Previous MI 50% 45%
Heart failure 7% 3%
Abnormal LV function 18% 17%
Peripheral vascular disease 13% 11%
Study
ARTS 40 539
BARI 163 729
ERACI-II 9 198
GABI 96 62
MASS II 10 188
RITA 126 364
SoS 36 451
Toulouse 34 42
ITA, Internal thoracic artery; LAD, left anterior descending coronary artery; MI, myocardi
BARI, Bypass Angioplasty Revascularization Investigation; ERACI-II, Argentine Random
Multivessel Disease; GABI, German Angioplasty Bypass Surgery Investigation; MASS-II
Treatment of Angina; SoS, Stent or Surgery.
830 The Journal of Thoracic and Cardiovascular Surgon, and stopped matching when propensity scores differed by more than
0.01.We required that each pair of patients be drawn from the same clinical
trial and be matched on the presence or absence of diabetes.
We assessed time to event for 3 major clinical outcomes: death, death or
myocardial infarction, and death or myocardial infarction or repeat revas-
cularization. These end points were defined by each trial using specific pro-
tocol definitions.
We used Cox proportional hazards models to analyze time-to-event out-
comes, and logistic regression to analyze angina at 1 year. We performed 2
sets of analyses for each outcome. In the first set of analyses, we compared
outcomes of patients with and without an ITA graft among all patients, ad-
justing for the patients’ baseline clinical characteristics (Table 1) and strat-
ifying by trial. In the second set of analyses, we compared outcomes of
patients with and without an ITA graft in the subset of patients who were
matched on propensity score, adjusting for baseline clinical characteristics
and stratifying by trial. All statistical analyses were performed with RVer-
sion 2.8.1 software.
The funding agencies for this study had no role in any of the following:
study design; data collection, analysis, or interpretation; writing the man-
uscript; and the decision to submit for publication. The studywas app roved
by the Stanford Institutional Review Board.RESULTS
Data on ITA usewere available for 3,087 patients who re-
ceivedCABG in one of 8 clinical trials. The 2,573 (83%) pa-
tients who received an ITA graft were significantly less
likely to be female or have heart failure or a priormyocardial
infarction and significantlymore likely to have proximal dis-
ease of the left anterior descending coronary artery or triple-Matched patients
P value No ITA (n ¼ 437) ITA (n ¼ 437) P value
.15 60.7 60.6 .74
.0002 28% 28% .84
.82 13% 13% 1.00
.62 44% 47% .35
.52 51% 52% .61
.18 23% 19% .11
<.0001 35% 34% .64
<.0001 29% 27% .49
.14 53% 52% .90
.04 49% 48% .70
.0005 5% 4% .22
.62 19% 19% .80
.13 13% 13% .89
40 40
152 152
9 9
54 54
10 10
116 116
35 35
21 21
al infarction; LV, Left ventricular; ARTS, Arterial Revascularization Therapies Study;
ized Study: Coronary Angioplasty with Stenting Versus Coronary Bypass Surgery in
, Second Medicine, Angioplasty or Surgery Study; RITA, Randomized Intervention
ery c October 2011
TABLE 2. Propensity score for receiving an ITA graft
Coefficient P value
Age, y (mean) 0.013 0
Female sex 0.485 .0001
Diabetes 0.072 .63
Hypertension 0.092 .42
Hyperlipidemia 0.014 .92
Current smoker 0.049 .72
Proximal LAD 0.697 <.0001
3-Vessel disease 0.298 .014
Unstable angina 0.024 .87
Previous MI 0.172 .12
Heart failure 0.973 <.0001
Abnormal LV function 0.006 .97
Peripheral vascular disease 0.013 .95
Study
ARTS Reference
BARI 0.883 <.0001
ERACI-II 0.458 .24
GABI 3.055 <.0001
MASS-II 0.082 .82
RITA 1.661 <.0001
SoS 0.056 .82
Toulouse 2.260 <.0001
Intercept 3.266 <.0001
ITA, Internal thoracic artery; LAD, left anterior descending coronary artery;MI, myo-
cardial infarction; LV, left ventricular; ARTS, Arterial Revascularization Therapies
Study; BARI, Bypass Angioplasty Revascularization Investigation; ERACI-II, Argen-
tine Randomized Study: Coronary Angioplasty with Stenting Versus Coronary By-
pass Surgery in Multivessel Disease; GABI, German Angioplasty Bypass Surgery
Investigation;MASS-II, Second Medicine, Angioplasty or Surgery Study; RITA, Ran-
domized Intervention Treatment of Angina; SoS, Stent or Surgery.
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Dvessel disease (Table 1). The use of ITA grafts also varied
significantly by trial, ranging from 39% to 96%. The multi-
variable propensity score showed that the strongest predictor
of whether a patient received an ITA graft was the trial in
which the patient was enrolled, followed by heart failure,
presence of disease in the proximal left anterior descending
coronary artery, female sex, and the presence of 3-vessel dis-
ease (Table 2). We were able to match on propensity scoreTABLE 3. Incidence of clinical outcomes in follow-up by use of the ITA ba
Outcome
All patients
No ITA
(n ¼ 514)
ITA
(n ¼ 2,573)
Un
P
Death (%)
5 y 10.4 7.8
10 y* 22.5 20.6
Death or MI (%)
5 y* 19.2 15.4
10 y* 33.3 30.4
Death, MI, or repeat revascularization (%)y
5 y* 20.1 14.3
10 y* 40.8 37.4
Angina at 1 y (%) 17.8 12.8
ITA, Internal thoracic artery; MI, myocardial infarction. *Kaplan–Meier estimates. yData
The Journal of Thoracic and Ca437 (85%) of the 514 patients who did not receive an ITA
graft with 437 patients from the same trial who did receive
an ITA graft. As expected, thematched groups had very sim-
ilar baseline characteristics (Table 1).
Among all patients receiving CABG, the median follow-
up of surviving patients was 6.7 years (interquartile range,
5.1–10.0 years), with a mean follow-up of 7.8 years and
a maximum follow-up of 16.3 years. The unadjusted Ka-
plan–Meier mortality rate at 5 years was 2.6% lower among
patients who received an ITA graft than among patients who
received vein grafts only, and at 10 years, the mortality rate
was 1.9% lower in the ITA group (Table 3). In a Cox model
that was stratified by study and adjusted for all of the base-
line characteristics in Table 1, use of an ITA graft was asso-
ciated with a significantly lower risk of death, with a hazard
ratio of 0.77 (confidence interval, 0.62–0.97; P ¼ .02). Use
of an ITA graft was also associated with a significantly re-
duced chance of the composite end point of death or myo-
cardial infarction and the composite end point of death or
myocardial infarction or repeat revascularization (Tables
3 and 4). Angina at 1 year was also less frequent among
patients who received an ITA graft, although not
significantly so (Tables 3 and 4).
Among 437 pairs of patients matched on propensity
score, study, and diabetes, 5-year mortality was 2.3% lower
among patients who received an ITA graft than among pa-
tients who did not, and at 10 years, mortality was 2.5%
lower in the ITA group (Figure 1 and Table 3). In a Cox
model stratified by study, use of an ITA graft was associated
with a lower risk of death, with a hazard ratio of 0.78 (con-
fidence limits, 0.57–1.05; P¼ .10). The hazard ratio was es-
sentially unchanged after additional adjustment for baseline
characteristics (0.77; confidence limits, 0.57–1.05;
P ¼ .10). There was a significantly lower incidence of the
composite end point of death or myocardial infarction
(MI; Figure 2 and Table 3) and of the composite end point
of death, MI, or repeat revascularization (Figure 3 and Table
3). Angina at 1 year was less frequent among patients whosed on pooled unadjusted data
Matched patients
adjusted
value
No ITA
(n ¼ 437)
ITA
(n ¼ 437)
Unadjusted
P value
.04 10.4 8.1 .12
.17 21.7 19.2 .18
.02 19.1 13.8 .02
.10 32.2 27.6 .07
.002 19.8 16.9 .14
.08 40.2 36.6 .14
.004 17.8 15.4 .17
omit the Toulouse study.
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TABLE 4. Comparative outcomes: Hazard ratio for ITA versus no ITA in Cox models stratified by study and adjusted for baseline clinical
characteristics
All patients (n ¼ 3,087) Matched patients (n ¼ 874)
Hazard ratio (CI) P value Hazard ratio (CI) P value
Death 0.77 (0.62-0.97) .02 0.77 (0.57-1.05) .10
Death/MI 0.83 (0.69-1.00) .05 0.78 (0.61-1.00) .05
Death/MI/repeat procedure 0.82 (0.69-0.98) .03 0.85 (0.67-1.08) .18
Angina* (1 y) 0.81 (0.61-1.09) .16 0.81 (0.55-1.19) .28
The data shown are odds ratios (95% confidence intervals). ITA, Internal thoracic artery; CI, confidence interval; MI, myocardial infarction. *Logistic regression model used to
assess angina at 1 year.
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Dreceived an ITA graft, although not significantly so (Tables
3 and 4).
DISCUSSION
Our analysis confirms that patients who receive ITA
grafts differ significantly from patients who receive only
vein grafts in a number of prognostically important clinical
characteristics (Table 1), including sex, a history of MI and
heart failure, and the extent of coronary artery disease
(Table 2). After adjusting for these and other differences
by using several different statistical methods, we found
that use of an ITA graft was associated with a 23% lower
relative risk of death over a 6.7-year median follow-up
(Table 4). These results are generally consistent with theYe
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832 The Journal of Thoracic and Cardiovascular Surg38% risk reduction over 10 years reported by Loop and as-
sociates,5 the 27% risk reduction over 15 years reported by
Cameron and coworkers,6 and the 32% risk reduction over
20 years reported by Cameron and colleagues.7 The long-
term risk reductions associated with use of ITA grafts are
not as striking as the 56% to 74% reductions in procedural
mortality reported by large clinical databases,15-18 but
comparisons of 30-day mortality after CABG might be
more susceptible to selection bias.
In addition to an association with lower mortality, ITA
use in our study was also associated with lower rates of
myocardial infarction, repeat revascularization, and angina
(Tables 3 and 4). The consistency of the effect of ITA use on
these additional end points is reassuring. Our results, inars
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Dconjunction with those of earlier studies,5,6 suggest that the
better long-term patency of ITA grafts seems to translate
into improved long-term clinical outcomes.
ITA grafting has not been tested in a large, long-term
clinical trial, and therefore nonrandomized observational
comparisons are the only source of information on the com-
parative effectiveness of ITA and vein grafts. Patients se-
lected for alternative treatments differ in a number of ways,
however, and therefore multivariable statistical methods
have been used in an attempt to adjust for clinically important
differences between patient groups. Avariety of methods has
been used,19 including direct adjustment for confounding
factors in amultivariable model, propensity score adjustment
and matching,8,9 and instrumental variables methods,20,21
among others. Typically, investigators choose just one of
these methods to analyze their data, but recent studies have
shown that the results of alternative models applied to the
same dataset might well differ.22,23 We applied several
approaches to the analysis of these data to evaluate whether
the results would be affected by the choice of a statistical
model. The magnitude of the effect of the ITA on several
outcome measures was quite similar whether we used
direct adjustment for baseline covariates or propensity
score matching, although the confidence limits were wider
when the sample size was reduced by matching. These
alternative approaches might have yielded similar hazard
ratios in the present study because some adverse prognostic
factors had a higher prevalence in the ITA group (3-vessel
disease and proximal left anterior descending disease),
whereas other adverse prognostic factors had a lower
prevalence in the ITA group (abnormal left ventricular
function and prior myocardial infarction). Consequently,
prognosis at study entry might have been relatively similar
in the ITA and vein graft groups because of offsetting
imbalances in different baseline characteristics.
Furthermore, all patients in this analysis had been selected
to participate in a clinical trial, which might have led to
a narrower range of clinical characteristics than seen in
unselected patients undergoing CABG. The similarity in
the results of alternative statistical approaches in our study
should not be interpreted because showing these methods
would yield equivalent results in other observational
treatment comparisons.
This study has a number of limitations. Although the data
were drawn from clinical trials of CABG and coronary an-
gioplasty, the use of ITA grafting was not randomized and
varied considerably among the participating trials and ac-
cording to patients’ characteristics. We had only relatively
simple clinical data available on all patients and therefore
were unable to adjust for characteristics, such as the extent
of atherosclerosis, and residual selection bias due to unmea-
sured confounders might be present.12 The length of follow-
up in this study (median, 6.7 years) might not have been
long enough to show the full clinical effects of ITA grafting834 The Journal of Thoracic and Cardiovascular Surgin light of the accelerated rate of vein graft failure after 7
years. Finally, all patients underwent CABG between
1988 and 2000 and might not completely reflect the results
of contemporary CABG, although all were treated in cen-
ters with excellent cardiac surgical programs.
In conclusion, these data provide additional evidence
that use of an ITA graft appears to improve long-term out-
comes after CABG and suggest that ITA use might be
a reasonable process measure of the quality of care for
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